{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T15:05:44Z","timestamp":1709046344669},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.bpg.2004.04.008","type":"journal-article","created":{"date-parts":[[2004,8,27]],"date-time":"2004-08-27T21:16:47Z","timestamp":1093641407000},"page":"773-786","source":"Crossref","is-referenced-by-count":23,"title":["Treatment options in irritable bowel syndrome"],"prefix":"10.1016","volume":"18","author":[{"given":"Michael J.G.","family":"Farthing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2004.04.008_BIB1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/bmj.310.6973.171","article-title":"Irritable bowel, irritable body, irritable brain?","volume":"310","author":"Farthing","year":"1995","journal-title":"British Medical Journal"},{"key":"10.1016\/j.bpg.2004.04.008_BIB2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/gut.27.1.37","article-title":"Non-colonic features of irritable bowel syndrome","volume":"27","author":"Whorwell","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB3","first-page":"512","article-title":"Prevalence of irritable bowel syndrome in chronic fatigue","volume":"30","author":"Gomborone","year":"1996","journal-title":"Journal of the Royal College of Physics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1053\/gast.2002.33584","article-title":"Evolving pathophysiologic models of functional gastrointestinal disorders","volume":"122","author":"Mayer","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.47.6.861","article-title":"The neurobiology of stress and gastrointestinal disease","volume":"47","author":"Mayer","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(96)90341-4","article-title":"Psychometric scores and persistence of irritable bowel after infectious diarrhoea","volume":"347","author":"Gwee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.04.008_BIB7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/gut.44.3.400","article-title":"The role of psychological and biological factors in post infective gut dysfunction","volume":"44","author":"Gwee","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-4453(94)94871-2","article-title":"Irritable bowel syndrome\u2014post Salmonella infection","volume":"29","author":"McKendrick","year":"1994","journal-title":"Journal of Infection"},{"key":"10.1016\/j.bpg.2004.04.008_BIB9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0163-4453(96)91715-6","article-title":"Post Salmonella irritable bowel syndrome\u20145 year review","volume":"32","author":"McKendrick","year":"1996","journal-title":"Journal of Infection"},{"key":"10.1016\/j.bpg.2004.04.008_BIB10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.314.7083.779","article-title":"Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome; postal survey of patients","volume":"314","author":"Neal","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1016\/j.bpg.2004.04.008_BIB11","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0016-5085(03)00324-X","article-title":"Postinfectious irritable bowel syndrome","volume":"124","author":"Spiller","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0016-5085(98)83103-X","article-title":"Evidence of inflammatory pathogenesis in post-infectious irritable bowel syndrome (abstr)","volume":"114","author":"Gwee","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/gut.47.6.804","article-title":"Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome","volume":"47","author":"Spiller","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB14","first-page":"210","article-title":"A comparison of 5-hydroxytryptamine staining in enterochronomaffin cells between irritable bowel syndrome and other gastrointestinal disorders","volume":"47","author":"Bose","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/gut.19.1.64","article-title":"Sensibility of the rectum to distension and the anorectal distension reflex in ulcerative colitis","volume":"19","author":"Farthing","year":"1978","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0016-5085(88)90319-8","article-title":"Controlled treatment trials in the irritable bowel syndrome: a critique","volume":"95","author":"Klein","year":"1977","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB17","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1053\/gast.1997.v112.agast972120","article-title":"Irritable bowel syndrome: a technical review for practice guideline development","volume":"112","author":"Drossman","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/gut.48.2.272","article-title":"Treatment of irritable bowel syndrome: a review of randomised controlled trials","volume":"48","author":"Akehurst","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(94)91055-3","article-title":"Bran and irritable bowel syndrome: time for reappraisal","volume":"344","author":"Francis","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.04.008_BIB20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.0269-2813.2004.01862.x","article-title":"Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome","volume":"19","author":"Bijkerk","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2036.1994.tb00322.x","article-title":"Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome","volume":"8","author":"Poynard","year":"1994","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"15","key":"10.1016\/j.bpg.2004.04.008_BIB23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.2001.00937.x","article-title":"Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome","author":"Poynard","year":"2001","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB24","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0140-6736(84)92793-4","article-title":"Control trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome","volume":"ii","author":"Whorwell","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.04.008_BIB25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/gut.28.4.423","article-title":"Hypnotherapy in severe irritable bowel syndrome; further experience","volume":"28","author":"Whorwell","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1752-0118.1991.tb01174.x","article-title":"A brief psychotherapy with patients with refractory IBS","volume":"8","author":"Guthrie","year":"1991","journal-title":"British Journal of Psychotherapy"},{"key":"10.1016\/j.bpg.2004.04.008_BIB27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00042737-199406000-00007","article-title":"The difficult patient: treating the mind and the gut","volume":"6","author":"Guthrie","year":"1994","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB28","first-page":"277","article-title":"Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials","volume":"91","author":"Talley","year":"1996","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9343(99)00299-5","article-title":"Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis","volume":"108","author":"Jackson","year":"2000","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.bpg.2004.04.008_BIB30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF02063948","article-title":"Effect of a tricyclic anti-depressant on small intestinal motility in health and in diarrhea-predominant irritable bowel syndrome","volume":"40","author":"Gorard","year":"1995","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.bpg.2004.04.008_BIB31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.35.4.496","article-title":"5 hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine uptake","volume":"34","author":"Gorard","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB32","series-title":"Basic Mechanisms of Digestive Diseases: The Rationale for Clinical Management and Prevention","first-page":"59","article-title":"Irritable bowel syndrome: new drugs and therapeutic horizons","author":"Farthing","year":"2002"},{"key":"10.1016\/j.bpg.2004.04.008_BIB33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/00365529109111236","article-title":"5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists","volume":"26","author":"Farthing","year":"1991","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199856010-00002","article-title":"New drugs in the management of the irritable bowel syndrome","volume":"56","author":"Farthing","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.bpg.2004.04.008_BIB35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/bega.1999.0040","article-title":"Irritable bowel syndrome: new pharmaceutical approaches to treatment","volume":"13","author":"Farthing","year":"1999","journal-title":"Bailliere's Clinical Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2982.1996.tb00270.x","article-title":"5-Hydroxytryptamine and functional bowel disorders","volume":"8","author":"Sanger","year":"1996","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1016\/j.bpg.2004.04.008_BIB37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.42.1.42","article-title":"Post-prandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome","volume":"42","author":"Bearcroft","year":"1998","journal-title":"Gut"},{"issue":"supplement 1","key":"10.1016\/j.bpg.2004.04.008_BIB38","doi-asserted-by":"crossref","first-page":"A636","DOI":"10.1016\/S0016-5085(01)83162-0","article-title":"Increased platelet storesof 5-hydroxytryptamine (5-HT) in female patients with diarrhoea predominant irritable bowel syndrome (IBS)","author":"Houghton","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB39","first-page":"99","article-title":"Different pathophysiological functions of 5-HT4 and 5-HT3 receptors in small and large intestine","volume":"3","author":"Sanger","year":"1998","journal-title":"Current Research in Serotonin"},{"key":"10.1016\/j.bpg.2004.04.008_BIB40","series-title":"5-HT4 Receptors in the Brain and Periphery","first-page":"213","article-title":"Therapeutic applications of 5-HT4 receptor agonists and antagonists","author":"Sanger","year":"1998"},{"key":"10.1016\/j.bpg.2004.04.008_BIB41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2036.1993.tb00087.x","article-title":"Reduction of rectal sensitivity and post-prandial motility by granisetron, 5-HT3 receptor antagonist, in patients with irritable bowel syndrome","author":"Prior","year":"1993","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2036.1993.tb00131.x","article-title":"Effect of a 5-HT3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome","volume":"7","author":"Hammer","year":"1993","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000201377","article-title":"Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)","volume":"57","author":"Goldberg","year":"1996","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2004.04.008_BIB44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1476-5381.1995.tb13263.x","article-title":"Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity","volume":"114","author":"Banner","year":"1995","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB45","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.04.008_BIB46","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(05)72978-0","article-title":"Alosetron for irritable bowel syndrome","volume":"356","author":"Barbehenn","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2004.04.008_BIB47","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.bpg.2004.04.008_BIB48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1358\/dof.1999.024.05.489133","volume":"24","author":"Rabasseda","year":"1999","journal-title":"Cilansetron Drugs of the Future"},{"issue":"15","key":"10.1016\/j.bpg.2004.04.008_BIB49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2036.2001.00925.x","article-title":"Review article: tegaserod","author":"Camilleri","year":"2001","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB50","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB51","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2004.04.008_BIB53","unstructured":"FDA talk paper, July 24, 2002. http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/2002\/ANS01160.html."},{"key":"10.1016\/j.bpg.2004.04.008_BIB54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2036.2004.01864.x","article-title":"Systematic review: incidence of abdominal\/pelvic surgery amongst patients using tegaserod in randomized controlled trials","volume":"19","author":"Schoenfeld","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB55","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome","volume":"95","author":"Pimental","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB56","doi-asserted-by":"crossref","DOI":"10.1023\/B:DDAS.0000011605.43979.e1","article-title":"A 14-day elemental diet is highly effective in normalizing lactulose breath test in IBS","volume":"49","author":"Pimentel","year":"2004","journal-title":"Digestive Diseases and Science"},{"key":"10.1016\/j.bpg.2004.04.008_BIB57","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/00042737-200110000-00004","article-title":"A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome","volume":"13","author":"Niedzielin","year":"2001","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB58","article-title":"Probiotics for the irritable bowel syndrome (IBS): A randomized, double-blind, placebo-controlled comparison of Lactobacillus and Bifidobacterium strains","volume":"122","author":"Quigley","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2004.04.008_BIB59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/089106001753341282","article-title":"Probiotics in the management of irritable bowel syndrome: a review of clinical trials","volume":"3","author":"Hamilton-Miller","year":"2001","journal-title":"Microbial Ecology Health Diseases"},{"key":"10.1016\/j.bpg.2004.04.008_BIB60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.2003.01640.x","article-title":"Spiller R Randomized, double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome","volume":"18","author":"Dunlop","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.bpg.2004.04.008_BIB61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2036.2004.01859.x","article-title":"Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled multi-centre trial","volume":"19","author":"Madisch","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169180400054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169180400054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T07:48:39Z","timestamp":1705218519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169180400054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S152169180400054X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2004.04.008","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}